Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer

Oncology

Volumn 56, Issue 3, 1999, Pages 232-238

  Yamane, Nariyuki ^a   Tsujitani, Shunichi ^a   Makino, Masato ^a   Maeta, Michio ^a   Kaibara, Nobuaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

CD44; Colorectal cancer; Prognosis; Soluble CD44 variant 6

Indexed keywords

CD44V ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 0032906045     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011970     Document Type: Article

References (34)

1. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61: 1303-1313.
2. Shimizu Y. Van Seventer GA, Siraganian R, Wahl L, Shaw S: Dual role of the CD44 molecule in T cell adhesion and activation. J Immunol 1989;143:2457-2463.
3. Harn HJ, Isola N, Cooper DL: The multispecific cell adhesion molecule CD44 is represented in reticulocyte cDNA. Biochem Biophys Res Commun 1991;178:1127-1134.
4. Screaton GR, Bell MV, Jacson DG, Cornelis FB, Gerth U, Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89:12160-12164.
5. Herrlich P, Zoller M, Pals ST, Ponta H: CD44 splice variants: Metastases meet lymphocytes. Immunol Today 1993;14:395-399.
6. Cooper DL, Dougherty G, Ham HJ, Jackson S, Baptiste W, Byers J, Datta A, Phillips G, Isola NR: The complex CD44 transcriptional unit: Alternative splicing of three internal exons generates the epithelial form of CD44. Biochem Biophys Res Commun 1992;182:569-578.
7. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
8. Heider KH, Hofmann M. Hors E, Berg F, Ponta H, Herrlich P, Pals S: A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinoma and adenomatous polyps. J Cell Biol 1993;120: 227-233.
9. Mulder JWR, Kruyl PM, Sewnath M, Oosting J: Seldenrijk CA, Weidema WF, Offerhaus GJA, Pals ST: Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994;344:1470-1472.
10. Nihei Z, Ichikawa W. Kojima K, Togo S, Miyanaga T, Hirayama R, Mishima Y: The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Surg Today 1996;26:760-761.
11. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS: Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994;54:422-426.
12. Harn HJ, Ho LI, Shyu RY, Yuan JS, Lin FG, Young TH, Liu CA, Tang HS, Lee WH: Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol 1996;22:107-110.
13. Gansauge F, Gansauge S, Rau B, Scheiblich A, Poch B, Schoenberg MH, Beger HG: Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma. Cancer 1997; 80:1733-1739.
14. Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A, Kainz Ch: Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 1995;72:1494-1497.
15. Kan M, Kanayama H, Naruo S, Tsuji M, Kojima K, Kurokawa Y, Kagawa S: Serological evaluation of soluble CD44 in renal cancer. J Cancer Res 1996;87:1191-1194.
16. Lein M, Jung K, Weiss S, Schnorr D, Loening SA: Soluble CD44 variants in the serum of patients with urological malignancies. Oncology 1997;54:226-230.
17. Japanese Society for Cancer of the Colon and Rectum: General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus 1994. Tokyo, Kanehara, 1994.
18. Whittaker M, Goligher JC: The prognosis after surgical treatment for carcinoma of the rectum. Br J Surg 1976;63:384-388.
19. Koopman G, Heider KH, Horst E, Adolf GR, van den Berg F, Ponta H, Herrlich P, Pals ST: Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 1993;177:897-904.
20. Friedrichs K, Franke F, Lisboa BW, Kugler G, Gille I, Terpe HJ, Holzel F, Maass H, Gunthert U: CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995;55:5424-5433.
21. Arch R, Wirth K, Hoffman M, Ponta H, Matzku S, Herrlich P, Zoller M: Participation in normal immune responses of a splice variant of CD44 that encodes a metastasis-inducing domain. Science 1992;257:682-685.
22. Heider KH, Dammrich J, Skroch-Angel P, Muller-Hermerink HK, Vollmers HP, Herrlich P, Ponta H: Differential expression of CD44 splice variants in intestinal and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993;53:4197-4203.
23. Tanabe KK, Ellis LM, Saya H: Expression of CD44R1 adhesion molecule in colon carcinomas and metastasis. Lancet 1993;341:725-726.
24. Matsumura Y, Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992;340:1053-1058.
25. Wielenga VJM, Heider KH, Offerhaus JA, Gunther RA, van den Berg F, Ponta H, Herrlich P, Pals ST: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53: 4754-4756.
26. Mulder JWR, Wielenga VJM, Polak MM, van den Berg F, Gunther RA, Herrlich P, Pals ST, Offerhaus JA: Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. Gut 1995;36:76-80.
27. Bourguignon LYW, Iida N, Welsh CF, Krongard A, Pasquale D: Involvement of CD44 and its variant isoforms in membrane cytoskeleton interaction, cell adhesion and tumor metastasis. J Neurooncol 1995;26:201-208.
28. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with the cellular matrix. Adv Immunol 1993;54:271-335.
29. Lesley J, Hyman R: CD44 can be activated to function as a hyaluronic acid receptor in normal murine T cells. Eur J Immunol 1992;22: 2719-2723.
30. Yang B, Yang BL, Savani RC, Turley EA: Identification of a common hyaluronan-binding motif in the hyaluronan-binding proteins RHAMM, CD44 and link protein. EMBO J 1994;13:286-296.
31. Stamenkovic I, Aruffo A, Amiot M, Seed B: The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 1991;10:343-348.
32. Kundson W, Biswas C, Toole BP: Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci USA 1984;81:6767-6771.
33. Thomas L, Byers HR, Vink J, Stamenkovic I: CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol 1992;118: 971-977.
34. Sleeman JP, Arming S, Moll JF, Hekele A, Rudy W, Sherman LS, Kreil G, Ponta H, Herrlich P: Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Cancer Res 1996;56:3134-3141.